Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.
Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH.
Zhang Y, et al. Among authors: zhang yq, zhang t.
Cell Rep Med. 2022 Nov 15;3(11):100814. doi: 10.1016/j.xcrm.2022.100814.
Cell Rep Med. 2022.
PMID: 36384091
Free PMC article.
Clinical Trial.